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DEVELOPMENT OF A HIGH-THROUGHPUT SYSTEM FOR SCREENING OF
ANTI-PRION MOLECULES

Katherine Pham Do, B.S.
Advisory Professor: Rodrigo Morales, PhD.

The misfolded prion protein causes and transmits disease in both humans and
animals. As other infectious agents, prions display strain variation, which can generate
different pathological outcomes in affected individuals. Unfortunately, there are no known
therapies for these diseases, which at present are invariably fatal. In this work, the
Protein Misfolding Cyclic Amplification technology (PMCA, an in vitro test that replicates
minimum quantities of infectious prions) has been modified to screen for small molecules
inhibiting

prion

protein

misfolding

in

a

strain-specific

manner. In order to approach a high-throughput PMCA system, technical aspects in
PMCA has been optimized for application of prions from laboratory rodents (i.e., mouse
and Syrian hamsters) using a 96-well plate PMCA (96wp-PMCA) platform. Utilizing the
96wp-PMCA technique, a small number of anti-prion and anti-amyloid molecules has
been tested against these prion strains using different solvents and at varying
concentrations. My results show that regardless of sequence homology, prion strains are
differentially responsive to known protein misfolding inhibitors. Continual optimization of
PMCA towards a high-throughput system may be used not only for screening therapeutic
agents but also for diagnosis.
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INTRODUCTION
The cellular prion protein (PrPC) is naturally found in humans and animals (1). This
protein can be found in a wide variety of tissues throughout the body. Specifically, it is
found in higher concentrations in the brain, spinal cord, and lymphoid tissues (2, 3). From
the cellular perspective, PrPC is located on the cell surface (4). Currently, the function of
this protein in physiological processes is unclear (5). However, proposed functions
associated with PrPC include protection of neurons from injury (6, 7), formation of
synapses (8), or transport of copper into the cell (9–11). PrPC has also been identified
as a possible receptor for amyloid-β (Aβ) oligomers which appear to be the main
pathological effectors in Alzheimer’s disease (AD). However, based on studies showing
that mice lacking the cellular prion protein display little or no abnormalities (12), it can be
concluded that its functionality is not considered to be vital for cellular homeostasis or
that its loss can be compensated for by other components. Under certain circumstances,
PrPC can misfold into a disease-causing form referred to as PrPSc (13). The length of
PrPSc and its amino acid composition are identical to PrPC. The difference between both
entities lies in the secondary structure of the protein, with PrPSc consisting of more bpleated sheets in comparison to a-helices found in PrPC (1, 14). Notably, the misfolded
form of the prion protein is known to cause and transmit a group of disorders termed as
Transmissible Spongiform Encephalopathies (TSEs, (15, 16)).
Prion diseases have been identified in several mammalian species, including
humans (17). Human prion diseases can be classified into three categories: acquired,
familial, and sporadic (18). Infection as a cause of human TSEs accounts for
approximately one percent of cases (WHO). In these cases, infectious prions have been
described as being introduced to humans through cannibalism (19), medical procedures
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(20–22), and ingestion of beef products derived from cattle afflicted by bovine spongiform
encephalopathy (23). Human exposure to these materials leads to diseases known as
Kuru (24), iatrogenic Creutzfeldt-Jakob Disease (iCJD, (25)), and variant CJD (vCJD,
(23, 26, 27)), respectively. Five to ten percent of cases can be classified as familial or
hereditary (WHO). In these cases, patients with CJD, Gerstmann Straussler-Scheinker
(GSS), and Fatal Familial Insomnia (FFI) can be found to have point mutations in the
gene encoding the prion protein, resulting in accelerated misfolding and stabilization of
the disease-causing PrP isoforms (28, 29). Similarly, as with other neurodegenerative
diseases, the majority of human prion diseases are identified to be sporadic. Patients
affected by sporadic cases are not infected or have a family history of the disease. This
latter group includes sporadic CJD (sCJD, (30)), sporadic fatal insomnia ((31), and
variable protease sensitive prionopathy (VPSPr, (32)). The events triggering the first
misfolded process in sporadic TSEs are unknown, and likely occur in a stochastic
manner (30). Prion diseases are not selective towards humans and affect animals as
well. In fact, the frequency of prion diseases in animals is significantly higher (33). There
are a few types of animal prion diseases that can be considered prevalent. These include
scrapie affecting sheep and goats (34), bovine spongiform encephalopathy affecting
cows (35, 36), and chronic wasting disease (CWD) affecting cervid (37). All these TSEs
have been found to exist in farm settings; however, only CWD has been identified in the
wild as well (38–40). Due to the epidemic associated with CWD and its unclear zoonotic
potential, this prion disease has recently gained research and public interest (41).
Currently, efforts are being made by the scientific community and regulatory agencies to
avoid unpleasant scenarios as the BSE epidemic that was experienced at the end of the
last century (42). When an infected animal is identified in a farm setting, all animals that
inhabit the same area are sacrificed in order to prevent the spreading of the disease. The
2

presence of an infectious animal in the wild can transport the disease across a large
geographical distance.
Both humans and animals affected by prion diseases develop unique pathological
features as assessed by post mortem examination of brain and some peripheral tissues
(43). These include spongiform degeneration (44), accumulation of disease-associated
prion conformers (PrPSc) (45), loss of function and death of neurons (13), microglial
activation (45), and astrocytes proliferation (46). Importantly, the clinical and pathological
manifestation of TSEs within and across species is diverse. Compelling evidence has
suggested that prion diseases originate from specific variants or “strains” of PrPSc (47).
It is speculated that these different variants are a result of distinctive tertiary and
quaternary conformations that PrPSc acquires (48). From a diagnosis standpoint, these
strains may have specific biochemical properties that facilitate their identification and
diagnosis (47). These biochemical characteristics, such as glycosylation pattern and
structure of the protein, are distinctive of strains behaving differently. This can pose an
obstacle in the pursuit of treatments against these diseases.
Currently, there are no cures or treatments against any type of prion disease in
both humans and animals. Different laboratories have attempted to prevent or delay the
onset of the disease. Most of these strategies have been assessed using in vitro assays
or animal models of TSEs (49, 50). Unfortunately, the majority of therapeutic approaches
have achieved modest effect through the extension of the incubation period for the
disease (51, 52). Therapeutic strategies explored against TSEs can be organized
broadly into three categories: (i) treatment-based approaches (gene therapy,
immunizations, manipulations at the immune system level, and cell-based therapies), (ii)
small molecules (altering either prion replication or cell signaling cascades), and (iii) prion
competition treatment. Some of these experimental approaches have been seen to delay
3

onset of the disease (53), act as a prophylaxis through protection from the disease (54–
56), or suppress prion replication (57). Unfortunately, the majority of these treatments
have only been tested against a select number of strains. Predominantly, these strains
belong to laboratory adapted rodent prion strains and not strains present naturally in
humans or animals. Due to the proposition that these strains are a result of different
conformations, an avenue that has shown promising results for one specific prion strain
may not be proficient against a second one (58).
To study prion diseases in the laboratory setting, animal models such as mice and
Syrian hamsters have been utilized (47). Unfortunately, there is a high monetary cost
associated with these models due to their long incubation periods for disease
manifestation (being as long as 450 days). Because of the need to test a large array of
compounds for activity against prion replication, this experimental format is unviable. The
Protein Misfolding Cyclic Amplification (PMCA) technique has been shown to replicate
conformational properties of infectious prions while maintaining their biologically relevant
features (59). This technique allows for the production of a large amount of the infectious
prion protein (PrPSc) at the expense of PrPC through multiple cycles consisting of
incubation and sonication (Figure 1). The incubation periods allow for the recruitment
and conversion of PrPC to PrPSc which adds to the PrPSc aggregates. In order to expose
more free ends of the aggregates to aid in the conversion process, sonication causes
the aggregate to be broken. Due to its sensitivity and simplicity, PMCA can be used for
several purposes, including: screening of biological samples (60), modeling of prion
strains and the species barrier phenomena (61), effectiveness of different strategies to
remove prions from biological samples (62), diagnosis of human and animal prion
diseases (63–65)), and many others.
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Incubation

Sonication

Incubation

Figure 1. Graphical representation for protein misfolding cyclic amplification. The
in vitro technique is based on the nucleation polymerization principle of protein
aggregation. The PrPSc aggregates recruits and converts PrPC during the incubation
period, and sonication allows for more free ends available to aid in the conversion
process. Multiple cycles of incubation and sonication occur during the PMCA process.
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For this master’s thesis, I focused on establishing a protocol that increases the
actual throughput of the PMCA technology with the goal to screen a small selection of
known anti-prion and anti-amyloid molecules. Six rodent prion strains associated with
mice and hamsters were chosen for this project. The mouse prion strains included the
Rocky Mountain Laboratory Strain (RML, (66, 67)), 301C (68), and ME7 (69–71)
(originated from scrapie, bovine spongiform encephalopathy, and scrapie, respectively).
Hamster prions comprised HY (72), SSLOW (73), and 263K (74) (with sources of scrapie,
in vitro misfolded recombinant PrP, and transmissible mink encephalopathy,
respectively). I chose these strains because they have been readily used to model and
study prion diseases in a laboratory setting and their distinct biochemical (and
presumably structural) features. My working hypothesis is that by modification of PMCA
for high-throughput screening of small molecules, I will find strain specific anti-prion
agents.
In order to utilize the PMCA technique to screen small molecules, I modified
PMCA for a 96-well plate (96wp) format for different prion strains. Modifications to
different parameters, including, but not limited to, composition of the PMCA conversion
buffer, alterations on incubation and sonication periods and sonication power, and signal
analysis performed via dot blotting, which is in considerably faster when compared to
currently used western blots, were made in order to standardize 96wp-PMCA. I aimed to
decrease the reagents needed and the time required for PMCA in order to advance the
technique in a high-throughput format.
After the standardization of 96wp-PMCA, I used this technique to screen a small
selection of molecules, which possess proven anti-prion capabilities in different systems
(mostly cell-based). Anti-prion molecules and anti-amyloid molecules were evaluated
against six rodent prion strains. The anti-prion molecules have been tested against a
6

selected number of prion strains belonging to human and animals (49, 75) while the antiamyloid molecules are compounds which have been shown to inhibit the replication of
non-prion amyloids (76).
From these aims, with the standardization of 96wp-PMCA and its application for
the screening of small molecules, I completed the main goal of identifying small
molecules able to inhibit the in vitro prion misfolding process against different strains.
The long-term goal will be for these identified molecules to be tested in animal models,
and prospectively utilized in clinical trials. Additionally, this technology may be optimized
to further increase its throughput and identify novel strain-specific inhibitors. In addition,
the standardized principles of the 96wp-PMCA platform could be applied towards other
diseases involving the accumulation of misfolded proteins, such as, Alzheimer’s and
Parkinson’s disease. The PMCA technique can be further modified and optimized in
order to attain a high-throughput screening system.

MATERIALS AND METHODS
Preparation of Brain Tissue
Wild-Type (WT) mouse or hamster brains were collected from animals euthanized by
CO2 inhalation based on University and Federal guidelines. After euthanasia, animals
were subjected to cardiac perfusion. Perfusion buffer was created by adding 5 mM EDTA
(Fisher Scientific Company PR-V4231) to 1X PBS (Fisher Scientific Company
SH30256LS). Each animal was manually perfused with 30 mL of perfusion buffer. After
perfusion, brains were removed, rinsed in perfusion buffer, frozen in liquid nitrogen and
stored at -80°C. Prion-Infected mice or hamsters were euthanized by CO2 inhalation once

7

reaching advanced clinical stages of prion disease as previously described (77, 78).
Collected brains were stored at -80°C until used.

Preparation of PMCA Substrate
Conversion Buffer (CB) was made consisting of: 150 mM NaCl (Sigma Aldrich S3014),
1% volume/volume (v/v) Triton X-100 (Sigma Aldrich T9284) and 1X PBS, pH 7.0-7.3.
Before use, 50 mL of CB was supplemented with a complete protease inhibitor (PI)
cocktail tablet containing EDTA (Thermo Fisher Scientific PIA32965). Perfused wild-type
brains were weighed and combined with conversion buffer (CB) containing PI to generate
a 10% weight/volume (w/v) homogenate that was prepared in ice-cooled Potter-Elvehjem
tissue grinders. Homogenates were centrifuged at 800 x g at 4°C for 45 s. Pellets were
disposed of while supernatants were well-mixed by vortexing and then placed on ice.
Supernatants were aliquoted, frozen in liquid nitrogen, and stored at -80°C. All the
procedures mentioned above were performed using prion-free facilities and equipment.
These aliquots, which are the final PMCA substrate, are referred to as normal brain
homogenate (NBH).

Preparation of Inoculum
The protocol is similar to the substrate preparation aside from the following:
homogenization buffer was prepared by mixing one complete PI tablet with EDTA in 1X
PBS. The prion-infected brain was homogenized in 10% w/v, as described above and
centrifuged. Supernatants were mixed, aliquoted and stored at -80°C until use.

8

96-well plate PMCA (96wp-PMCA)
PMCA protocol was extensively modified from previously described procedures (79).
Two teflon beads (PTFE Grade Balls 3/32) (Hoover Precision Products) were added to
each well of 96-well plates (Thomas Scientific C18096). Prions were added to each well
in amounts varying from 1 x 10-2 to 1 x 10-5 % w/v brain homogenate equivalent by dilution
in NBH. Each reaction was performed in a total volume of 50 μL. Samples were covered
with twelve strip lids (Thomas Scientific C18096-C) and plates were placed in the horn
of a Qsonica Q700 automatic sonicator system. The overall length of each passage was
between 24 and 48 hrs. Each PMCA cycle consisted of continuous cycles of 29 min and
40 s of incubation followed by 20 s of sonication. During the PMCA procedure, the
sonicator horn is inside an incubator set at 37°C. PMCA reactions were additionally
supplemented with different concentrations of ethanol or dimethyl sulfoxide, or small
molecules dissolved in these solvents (small molecule concentrations varying from 100
µM to 0.1 µM). Negative controls consisted of unseeded PMCA reactions.

Analysis of 96wp-PMCA Products
Each well from 96wp-PMCA was treated with proteinase K (PK) (Sigma Aldrich P2308)
at a 100 μg/mL final concentration. After PK was added to the wells, the plate was placed
in an Eppendorf Thermomixer for 1 hr at 37°C set to perform 450 rpm. To stop the PK
reaction, 5 mM of phenylmethane sulfonyl fluoride (PMSF) (Fischer Scientific Company
AC215740050) was added to each well and incubated at 70°C for 10 min. Samples were
then assessed for the presence of PK-resistant PrP either by western blot or dot blot. For
dot blots, Whatman Gel Block Paper (GE Healthcare Life Science 10427812) was placed
onto a Bio-Dot Apparatus (Bio-rad 1706455) followed by a nitrocellulose membrane
9

(Fischer Scientific Company 45-004-003). From each well, 5 μL of content was placed
directly onto the nitrocellulose membrane. Membranes were dried using a blow dryer and
then transferred into an incubation chamber containing 10 mL of 3M guanidinium
thiocyanate (Fischer Scientific 50-491-761) for 10 min. Later, membranes were rinsed
three times with 50 mL of washing buffer (0.05% Tween in 1X PBS) and then transferred
to a 10% blocking solution consisting of 5% w/v dry nonfat milk (Fischer Scientific
Company NC9952266) dissolved in washing buffer. Membrane blocking lasted 1 hr and
was performed by placing the membrane on a rocking platform at room temperature. The
membrane was later incubated with monoclonal 6D11 anti-prion antibody (Santa Cruz
Biotechnology sc-58581) at a 1:10,000 dilution in 5% w/v blocking buffer for 1 hr on a
rocking platform at room temperature followed by 3 washes (10 min, 5 min, and 5 min)
with washing buffer. Membranes were then incubated with a horseradish peroxidaselinked polyclonal antibody mouse IgG (Sigma Aldrich A5906) at a dilution of 1:3,000 in
5% w/v blocking buffer for 1 hr on a rocking platform at room temperature. The membrane
was again washed for 10 min, 5 min, and 5 min with washing buffer and developed using
an ECL system following manufacturer’s recommendations (Fisher Scientific 45-002401). For western blots, a similar procedure was performed, with the difference that PK
digested samples were previously fractionated in SDS-PAGE and transferred to
nitrocellulose membranes as described (79).

RESULTS
Optimization of Parameters for Dot Blot Analysis
Conventional PMCA procedure classically involves detection of PrPSc signals by
western blots (79). The utilization of conventional PMCA could be an option for the
screening of small molecules. However, I chose to optimize conventional PMCA for a 9610

well plate format because the amount of time involved could be drastically reduced by
the use of an alternative detection method, increasing the throughput and number of
samples to be analyzed. I chose the dot blot method due to its proven efficiency for prion
detection (80), the reduced time of this technique compared to western blots, and the
reduced volume of sample needed to obtain clear readouts. Aside from alterations to the
PMCA process, analyzing the samples with dot blots should reduce analysis times from
two days to one day compared to currently used western blots.
In order to achieve a high-throughput PMCA screening system in the future
through further modifications, the levels of samples for the assay and detection should
be reduced. In that sense, the minimum volume of PMCA products to be used in dot blots
must be determined. Importantly, positive readings obtained at the selected volume
should be homogeneous across the plate. For that purpose, I used a 10% w/v brain
homogenate from a mouse infected with the RML prion strain. Three different volumes
were utilized, including 3 μL, 5 μL, and 7 μL (Figure 2). These volumes are substantially
lower than the 20-30 µL regularly utilized in western blot detection (79). Ninety-six
aliquots of the same brain preparation were placed directly on the nitrocellulose
membrane. Because the samples used consisted of concentrated infectious material, I
expected that positive signals should be detected throughout the entire membrane. All
dot blots in this project were evaluated in an all-or-none fashion. These membranes did
not contain negative control wells in order to assess for uniform signal across the plate.
With only 3 µL used, signal was not uniformly detected for all the samples (Figure 2A).
On the contrary, both the volumes of 5 µL and 7 µL generated uniform results across the
plates. These experiments were performed in duplicates with reproducible outcomes. I
determined the optimal minimum volume of the samples required for analysis to be 5 µL
due to the desire to use the lowest sample volume possible.
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Figure 2. Effects of sample volume utilized in dot blot analysis. Three different
volumes (3μL (A), 5μL (B), and 7μL (C)) of 10% weight/volume (w/v) brain homogenate
prepared from the brain of a terminally ill mouse infected with the Rocky Mountain
Laboratory (RML) prion strain were directly placed on nitrocellulose membranes as
described in Methods. These samples were not PK-treated.
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In addition to the reduction in sample volume, processing time was decreased as
well. A major time constraint in the classical PMCA setup is seen in the primary antibody
incubation time. Based on current western blot protocols used to analyze PMCA
products, the standardized time required for primary antibody incubation is sixteen hours
(81, 82). Considering that several primary antibodies work at one hour of incubation (79,
83), I decided to try the same on my developing dot blot protocol. Similar to the
experiments shown in Figure 2, I used 10% w/v brain homogenate from a terminally ill
mouse brain infected with the RML prion strain as sample. Ninety-six aliquots of 5 μL
each of this material were loaded directly on the nitrocellulose membrane. For
comparison, two incubation times were tested (1 and 16 hrs, Figure 3). I concluded that
one hour of primary antibody incubation was sufficient for the dot blot to yield positive
signals in all wells, similar to what was observed by incubating the membrane with the
conventional 16 hours. The reduction of the primary antibody incubation duration
contributed to the decrease of time required for the analysis of the samples.
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Figure 3. Reduction of primary antibody incubation times does not affect dot blot
readout. 5 µL aliquots from a 10% weight/volume (w/v) brain homogenate prepared
using a brain from terminally ill mice infected with the Rocky Mountain Laboratory (RML)
prion strain were directly placed on nitrocellulose membranes. These samples were not
PK-treated. Primary antibody (6D11) incubation was tested for two different durations,
lasting either 1 hr (A) or 16 hrs (B).
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Optimization of the 96wp-PMCA
The next step was to modify PMCA with the intention of optimizing it towards a
high-throughput format. For that purpose, I modified this technique for its use in 96-well
plates instead of currently used individual tubes.

While using plates, I tested

modifications of PMCA components such as passage duration, sample volume in each
well, and specifications of the sonicator to accommodate for the number of samples.
Current settings used in conventional PMCA may work differently in the 96 well plate
format and should be tested. Based on previous research performed, the PMCA process
may require supplementation in order to work efficiently (79). Ethylenediaminetetraacetic
acid (EDTA) is a chelating agent that binds to divalent cations, particularly copper (II)
ions in solution. Divalent cations have been shown to inhibit prion replication in PMCA
(84, 85) Similar results have been observed for prions bound to metallic surfaces where
the release of cations into the PMCA reaction are likely the cause for reduced or no
replication ((86) and unpublished data). Due to the interaction that occurs between the
prion protein and divalent ions, the usage of EDTA can prevent unwanted interactions
and allow for PMCA to be more efficient. I tested two concentrations of EDTA in 96wpPMCA, including 0 mM (using protease inhibitor that was EDTA-free) and 1 mM (using
a complete protease inhibitor) supplemented into normal brain homogenate containing a
1x10-4 % w/v dilution of an RML-infected brain homogenate. Samples from both tested
conditions were PK treated prior to dot blot analysis. My results showed no signal for
samples in the EDTA-free context while in the presence of 1 mM EDTA uniform positive
signals were seen (Figure 4A). I concluded that in the absence of EDTA, the PMCA
process is hindered and 1 mM of EDTA is required for PMCA to work efficiently.
To further reduce the time required for HT-PMCA, I needed to reduce the number
of incubation/sonication cycles. In traditional PMCA, multiple passages (rounds) each
15

involving several incubation/sonication cycles are required (79). Each PMCA round
classically comprises durations between 24 hrs and 72 hrs. Extended times per PMCA
round are required to obtain a uniform amplification throughout all samples placed in the
sonication horn (79). For my assay, I decided to test 24 and 48 hrs in a single PMCA
round. I observed comparable results for both times tested and selected the one of 24
hrs cycle time for further assays (Figure 4B).
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Figure 4. Effects of EDTA supplementation and PMCA passage duration in 96wpPMCA. Modifications to optimize PMCA for a 96 well-plate format included changes at
the conversion buffer and incubation/sonication levels. (i) Normal wild-type brain
homogenate (PMCA substrate) was subjected to 0 mM (A) or 1mM (B) of EDTA
supplementation in conversion buffer used to homogenized samples. Normal brain
-4

homogenate was utilized to make a 1 x 10 % w/v RML brain homogenate dilution and
subjected to one PMCA passage of 24 hrs. (ii) Similar samples as described in (A) (EDTA
supplemented) were subjected to PMCA passages of 24 hrs (C) or 48 hrs (D).
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As previously stated, the amount of PrPSc seeds in the PMCA reaction was
another component which required optimization in order to approach this technique for a
high-throughput format. Therefore, it was essential to determine the lowest dilution that
can be utilized without jeopardizing uniform amplification of prions across all positions in
the 96-well plate. The main purpose of manipulating PMCA for a 96-well plate was to
provide a new avenue to use the technique for the screening of small molecules;
therefore, the lower dilution would be beneficial to maximize the probability of identifying
prospective molecules while also isolating efficient drugs. I tested, in my developing
96wp-PMCA assay, four concentrations of RML prions in regards of the dilution of an
infected brain homogenate: 1 x 10-2, 1 x 10-3, 1 x 10-4 and 1 x 10-5 % w/v (Figure 5).
PMCA products derived from each of the four dilutions were PK-treated and analyzed.
Uniform amplification can be seen at all four concentrations. When the dilution of 10-5
was tested against the other prion strains of interest, I was unable to detect uniform
amplification of the samples (not shown). After testing the dilution of 1 x 10-4 % w/v for
other strains, I was able to conclude that the appropriate dilution across multiple strains
would be 1 x 10-4% w/v.
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Sc

Figure 5. Effects of varying PrP

dilutions in 96wp-PMCA performance. Varying
-2

-3

-4

dilutions of RML brain homogenates (1 x 10 (A), 1 x 10 (B), 1 x 10 (C), and 1 x 10

-5

(D) % w/v) were tested for detection using 96wp-PMCA for 24 hrs. All PMCA products
were PK treated before analysis through dot blots.
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In summary, my modifications to use PMCA in a 96 well plate format included the
supplementation of 1 mM EDTA into the normal brain homogenate (Figure 4A) and
supplementation of seeds at a 1 x 10-4 % w/v dilution of infected brain homogenate
(Figure 5B). These conditions fulfilled my requirements of uniform amplification across
the 96 well plate for multiple rodent prion strains. Aside from alterations to the actual
PMCA process, I made other changes including the utilization of two teflon beads each
in comparison to three teflon beads, and reduction of the overall volume in well from 90
µL to 50 µL. Comprehensively, these changes allow for PMCA to be modified for a
scheme that is more optimal for the screening of small molecules targeting the prion
misfolding process. A summary of the changes implemented for the 96wp-PMCA
compared to conventional PMCA are listed in Table 1.
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Standardization of Experimental Prion Strains
Based on the parameters established above, I tested the in vitro amplification
performance of six rodent prion strains. Specifically, I used three mouse-derived prion
strains (RML (66, 67), 301C (68), and ME7 (69–71)) and three hamster-derived prion
strains (HY (72), SSLOW (73), 263K (74)). All these strains originated from different
sources, including sheep (RML, ME7), goat (263K), mink (HY), bovine (301C) prions, or
synthetically derived (SSLOW). The Rocky Mountain Laboratory (RML) strain was
chosen because several compounds halting its replication have been identified (49). The
other strains were chosen based on their suspected different conformations. As
mentioned, my working hypothesis is anti-prion molecules will have different responses
depending on the prion strain that they are tested against. Each of these six strains were
subjected to 24 hours of 96wp-PMCA at a 1 x 10-4 % w/v brain dilution of seeds.
Additionally, 4-6 negative control (non-seeded) samples were included to assess for
possible cross-contamination during PMCA and handling of samples. After PMCA, all
samples were PK-treated to remove non-misfolded PrP and 5 µL from each well were
dispensed onto nitrocellulose membranes for analysis. I observed uniform amplification
for the mouse and hamster prion strains (Figure 6 and Figure 7, respectively). Negative
control samples resulted in no signal, as expected. I further confirmed the presence of
bona-fide PrPSc by western blot (not shown).
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Figure 6. Standardized 96wp-PMCA for three mouse prion strains. From top to
bottom, 10

-4

dilutions of RML (A), 301C (B), and ME7 (C) prions, respectively, were

subjected to 24 hrs of 96wp-PMCA. Each plate contained 4-6 negative control wells as
depicted in white on the corresponding diagram (left panels). In these control samples,
Sc

no PrP

added as described in Methods.
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Figure 7. Standardized 96wp-PMCA for three hamster prion strains. From top to
-4

bottom, 1 x 10 % w/v dilutions of HY (A), SSLOW (B), and 263K (C) prions, respectively,
were subjected to 24 hrs of 96wp-PMCA. Each plate contained 4-6 negative control wells
Sc

as depicted in white on the corresponding diagram. In these control samples, no PrP
added as described in Methods.
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Due to the intention of testing a wide range of molecules, and in order to account
for molecule solubility in varying solvents, I tested the effect of dimethyl sulfoxide (DMSO)
and Ethanol (EtOH) on 96wp-PMCA performance. This experiment was necessary in
order to determine that the effects seen in the presence of the tested compounds were
not due to the solvents in which they were dissolved. Plates were set up with two strains
from each animal species, specifically RML and 301C for mice and HY and 263K for
hamsters. For all prion strains, a 1:2 dilution gradient was set up for each of the solvents
(starting from 8% v/v of solvent in each case). As seen in Figure 8, amplification of the
mouse prion strains displayed inhibition only at 8% EtOH but no inhibition at any of the
DMSO concentrations tested (Figure 8A). For hamster prions, inhibition of 263K
replication was seen at 8% ethanol, while HY displayed inhibition with EtOH at 8% and
4% (Figure 8B). Overall, these data suggest that PMCA is impacted at these specific
concentrations; therefore, molecules should be dissolved in concentrations where
inhibition is not seen. I therefore dissolved all compounds in 1% v/v of solvent and tested
their effects on in vitro prion replication using my 96wp-PMCA format.
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Figure 8. Effects of drug solvents in 96wp-PMCA. Prospective solvents, DMSO and
ethanol, were tested at eight different concentrations (ranging from 8% to 0.0625%)
against two mouse strains (A) and two hamster strains (B).
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Evaluation of compounds in 96wp-PMCA
Next, the optimized 96wp-PMCA set up was used to test the effect of a small
selection of known anti-prion (Figure 9) and anti-amyloid (Figure 12) molecules against
the six prion strains previously shown to replicate in this format. The majority of the antiprion molecules were chosen due to their previously reported effectiveness against RML
prions in a cell-based in vitro assay (49). The six anti-amyloid molecules chosen in this
thesis work have been previously tested for their activity against misfolded proteins
involved in Alzheimer’s and Parkinson’s Disease (76, 87, 88). Importantly, the anti-prion
activity of the latter set of compounds has not been studied. All compounds were
dissolved, based on their solubility, in either 1% v/v DMSO or 1% v/v ethanol. In the
appropriate solvents, four concentrations (100 µM, 10 µM, 1 µM, and 0.1 µM) of each
molecule were used to supplement 96wp-PMCA reactions. The total volume of each well
after the addition of the molecules was 50 µL as described in my previous optimization
of the assay. Each 96-well plate also contained proper controls, including negative
control samples and seeded wells supplemented with solvents only. To assess for
reproducibility, each condition was tested in triplicates (each replicate in a different plate).
The mouse strains (RML, 301C, and ME7) were tested against ten anti-prion
molecules; astemizole, Congo red, curcumin, quinacrine dihydrochloride, imatinib,
resveratrol, tannic acid, tetracycline hydrochloride, thioflavin T, and tetrandrine (Figure
10). Each of these molecules have been tested against a select number of strains for its
inhibitory effects in varying models. From the ten molecules tested, inhibition in prion
replication was observed only with three of the them (Congo red, tannic acid, and
thioflavin T). Although the same three molecules were effective against all three mouse
strains, a difference in lowest concentration of inhibition was seen for two of them: Congo
red and thioflavin T. For 301C prions (Figure 10B), both of these molecules displayed
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inhibition at 10 µM. This was different from the 100 µM effective concentration observed
for RML prions (Figure 10A). In comparison to the other two mouse prion strains, ME7
(Figure 10C) was only inhibited by tannic acid. When these anti-prion molecules were
tested against the hamster prion strains (HY, SSLOW, and 263K, Figure 11), Congo red,
tannic acid, and thioflavin T caused inhibition of these strains as well. In addition to those
three molecules, curcumin was shown to inhibit HY at 100 µM when dissolved in EtOH
(Figure 11A). This molecule also inhibited 263K misfolding at 100 µM in both solvents
(Figure 11C). Table 2 and Table 3 summarize the lowest concentration of compounds
capable of inhibiting in vitro replication on each prion strain. These results support my
hypothesis that the effectiveness of molecules with anti-prion activity may vary
depending on the prion strain that is tested.
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Figure 9. Selection of anti-prion molecules. Ten known anti-prion compounds were
chosen to be evaluated for inhibitory effects in 96wp-PMCA against rodent prion strains.
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Figure 10. Evaluation of known anti-prion small molecules in 96wp-PMCA (mouse
prion strains). Ten known anti-prion compounds were tested at four different
concentrations in either DMSO or EtOH for their activity against RML (A), 301C (B), and
ME7 (C) in vitro replication. Each molecule was tested in concentrations ranging from
100 µM to 0.1 µM. Controls for solvents and positive samples and negative samples
without compounds were included to monitor the assay. Dot blots were modified for
labeling. Figure is representative from three independent assays.
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Figure 11. Evaluation of known anti-prion small molecules in 96wp-PMCA (hamster
prion strains). Ten known anti-prion compounds were tested at four different
concentrations in either DMSO or EtOH for their activity against HY (A), SSLOW (B), and
263K (C) in vitro replication. Each molecule was tested in concentrations ranging from
100 µM to 0.1 µM. Controls for solvents and positive samples and negative samples
without compounds were included to monitor the assay. Dot blots were modified for
labeling. Figure is representative from three independent assays.
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The replication of mouse prion strains (RML, 301C, and ME7) was also tested in
the presence of six molecules; azure A, azure B, azure C, quinacrine mustard
dihydrochloride, rhodanine, and thionin acetate salt, proven to be active against other
amyloidogenic proteins (76) (Figure 13). Assays were performed in a similar fashion as
depicted in Figure 10. From the six tested molecules, four of them inhibited replication
for all mouse prion variants (azure A, azure B, azure C, and thionin acetate). Specifically,
azure B and azure C were effective at 1 µM against RML (Figure 13A) and ME7 (Figure
13C). The four molecules that displayed inhibition did so at different concentrations that
were dependent on the prion strains they were evaluated against. In a similar trend to
the anti-prion molecules, I am able to see strain specific patterns of inhibition for the antiamyloid molecules as well. In addition to the four molecules that were effective against
mouse strains, quinacrine mustard showed clear anti-prion activity against all the
hamster prions tested in this project (Figure 14). Although inhibition was detected across
the three hamster prion strains, it is important to acknowledge that effect occurred only
at the highest concentration tested (100 µM). The molecule displaying the lowest antiprion activity against hamster prions was azure C (effective at 1 µM against HY prions)
(Figure 14A). Table 3 summarizes the lowest concentration displaying anti-prion activity
each hamster prion strain for both anti-prion and anti-amyloid molecules. When
evaluating the results across both species and both groups of molecules, it becomes
evident that there may be a prion strain selective pattern of activity. Depending on the
strain that the molecule was tested against and the solvent, a selection of the compounds
was discovered to have distinct inhibition concentrations.
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Figure 12. Selection of anti-amyloid molecules. Six known anti-prion compounds
were chosen to be evaluated for inhibitory effects in 96wp-PMCA against rodent prion
strains.
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Figure 13. Evaluation of known anti-amyloid small molecules in 96wp-PMCA
(mouse prion strains). Six known anti-amyloid compounds were tested at four different
concentrations in DMSO and EtOH for their activity against RML (A), 301C (B), and ME7
(C) in vitro replication. Controls for solvents and positive samples and negative samples
without compounds were placed on the plate to control the performance of the assay.
Dot blots were modified for labeling. Figure is representative from three independent
assays.
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Figure 14. Evaluation of known anti-amyloid compounds in 96wp-PMCA (hamster
prion strains). Six known anti-amyloid compounds were tested at four different
concentrations in DMSO and EtOH for their activity against HY (A), SSLOW (B), and
263K (C) in vitro replication. Controls for solvents and positive samples and negative
samples without compounds were placed on the plates to control the performance of the
assay. Dot blots were modified for labeling. Figure is representative from three
independent assays.
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DISCUSSION AND CONCLUSION
The Protein Misfolding Cyclic Amplification (PMCA) technology was an
appropriate option to be used for this project due to (i) its ability to replicate the
conformational properties of infectious prions while maintaining all their biologically
relevant features (including strain specific properties, (61)), (ii) each assay can be
completed in a relatively short time, (iii) it represents a low cost technology, suitable for
screening large number of samples. Based on the other applications of PMCA, I believed
that the technique could be optimized for high-throughput identification and evaluation of
small molecules with presumed anti-prion activity.
High-throughput screening (HTS) allows for a large number of samples to be
tested against a specific target. This is performed by the utilization of automatization and
reduction of assay components allowing for the process to occur effectively, efficiently,
reproducibly and at minimum cost (89). A selected number of modifications would need
to occur in order to achieve the development of a high-throughput PMCA (HT-PMCA)
platform. In my project, I did not achieve the establishment of a HT-PMCA platform since,
at its current status, my optimized platform allows the screening of compounds at a
medium throughput range. However, I believe that the establishment of a 96-well plate
PMCA (96wp-PMCA) assay represents an important step forward in that direction.
Modifications of PMCA that I aimed to achieve with the 96wp-PMCA included the
decrease amount of time and volume that is required to complete the assay. In
comparison to conventional PMCA, I also decreased the number of teflon beads
required, lowered the volume of material to be utilized, substantially increased the
number of samples to be tested per PMCA assay, and decreased the length of the overall
process (Figures 2-5 and Table 1). All these manipulations were effective in reducing the
overall cost associated with this technique.
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The first step on this optimization path was to determine the minimum volume of
samples that would be required to allow for proper analysis. Importantly, the selection of
such volume should fulfill the criteria of being reproducible across the whole 96 well plate
in independent assays. In order to establish this volume, it was crucial to determine the
volume that would be required to evaluate the samples with dot blot. I directly placed
three different volumes of 10% w/v brain homogenate prepared from terminally ill mice
infected with the RML prion strain onto a nitrocellulose membrane (Figure 2). From this
experiment, I determined the volume of the sample required for dot blot analysis to be 5
μL. In parallel, I also determined that the PMCA reaction can be performed in a volume
as low as 50 μL. The latter assay volume was determined to be the minimum possible
since it allows for 2 teflon beads to be completely submerged (Teflon beads are known
enhancers of PMCA while buffering reproducibility across different assays (90–92)). The
beads are able to assist in the breaking of the PrPSc and provide additional surface area
for the conversion of PrPC to PrPSc to occur. A significant amount of time in the
conventional PMCA assay was attributed to the incubation period of the primary
antibody. Therefore, it was my goal to decrease the time dedicated to this critical step
(Figure 3). Since I saw comparable results when comparing the 16 hrs and 1 hr
incubation time, I was able to determine that 1 hour was sufficient for my purposes.
I can see that PMCA is unable to occur effectively when EDTA is not
supplemented into the brain homogenate (Figure 4). Although the mechanism is unclear,
the presence of cations has been hypothesized to prevent or delay the replication
process (84, 85). Since PMCA is a process that focuses on protein-protein interactions,
I hypothesize that the cations in solution may be interacting with either PrPSc or PrPC
preventing the desired interaction to occur. Consequently, the usage of 1 mM EDTA is
shown to render these cations unable to hinder the PMCA process. The purpose of the
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results shown in Figure 5 focused on finding the lowest dilutions where amplification can
be seen uniformly across the plate. I was able to see uniform amplification for the RML
strain at 1 x 10-5 % w/v; however, for other strains (not shown) uniform amplification was
only seen up to a dilution of 1 x 10-4 % w/v. In that sense this dilution of infectious prions
was used to supplement the 96wp-PMCA reactions in future assays.
With the transition from using PCR strip tubes to a 96-well plate, it was necessary
to optimize 96wp-PMCA for more than one prion strain. Optimizing the platform for a
selection of strains allows for the accommodation of different species and distinct
characteristics associated with each strain. Importantly, and due to the high sensitivity of
the PMCA assay (93), I had to verify the validity of the technique through the presence
of negative control samples (to assess for possible inter-well cross-contaminations). The
first step included testing the performance of six different rodent prion strains in my
assay, considering all above-mentioned optimized conditions and requirements. In
summary, I successfully achieved optimal 96wp-PMCA assays for mouse (Figure 6) and
Syrian hamster (Figure 7) prions. Through the random placement of negative controls
for each of the prion strains tested, I am able to conclude that uniform amplification of
the samples occurred regardless of their placement location on the plate. Biochemically,
prion strains can be distinguished by western blot due to their differential PK resistant
core (different lengths) or their glycosylation profiles (47). One of the limitations of using
dot blots for analysis of PMCA-derived samples from multiple strains is the incapability
to distinguish them. To account for this restriction, each assay only tested a single prion
strain and the signal was assessed in an all-or-none fashion. However, to verify that the
PMCA did not alter the strain properties of each selected agent, I ran selected samples
by western blots (not shown).
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The next step in my proposed project was to validate the 96wp-PMCA assay for
the screening of small molecules harboring anti-prion activity. As regular practice,
compounds from libraries are dissolved in different solvents, DMSO and EtOH being the
most widely used. These solvents were evaluated independently in the 96wp-PMCA to
determine if they would influence the prion replication process. Inhibition was seen at 8%
v/v EtOH in both mouse and hamster prion strains. Additionally, I also observed inhibition
at 4% EtOH with the HY prions (Syrian hamster strain). On the other hand, I did not see
any inhibition with DMSO at any of the concentrations tested for the mouse or hamster
strains. Despite the ability for these solvents to inhibit the in vitro conversion of some of
the tested prion strains, I was not majorly concerned since I dissolved all molecules at
1% v/v of each or both solvents. Since the solvent concentration chosen does not show
hinderance of in vitro conversion, any inhibition observed in the presence of small
molecules can be attributed to the molecule itself.
The majority of the anti-prion molecules tested in this study (Figures 10 & 11) were
selected on their ability to inhibit RML in neuroblastoma cell lines at nanomolar
concentrations (49). Thioflavin T was chosen as a molecule to test due its ability to
nonselective intercalate into the backbone of several classes of amyloids (94, 95). Since
my paradigm consists of an in vitro platform for the conversion of PrPC to PrPSc, I
hypothesize that effective molecules will influence protein protein interactions through
(i) binding to the PrPC and preventing its conversion to PrPSc, (ii) binding to PrPSc and
prevent the recruitment of PrPC, (iii) targeting the particular glycosylation preferences of
each prion strain, or (iv) binding to still unknown co-factors present in the brain
homogenate that could alter the conversion of each specific prion strain.
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Only three of the anti-prion molecules were effective against one or more mouse
prion strains (Figure 10). Specifically, all three strains were inhibited by 10 µM tannic
acid; however, strain specific inhibition was seen for Congo red and thioflavin T. Although
RML and ME7 are both derived from scrapie (47), they did it from different sources of
this infectious agent. Consequently, both mouse-adapted prion strains display different
glycosylation profiles and generate different lesion patterns in brains of experimental
subjects. This information strongly supports the notion of both being different
“conformational” strains, and that may be a leading reason as to why Congo red and
thioflavin T inhibited RML but not ME7. Congo Red did not show selective strain inhibition
for the hamster prion strains tested in this study, even at the highest concentration tested
(100 µM). In the same line, I observed that curcumin selectively inhibited the replication
of HY and 263K prions, but not SSLOW (Figure 11).
Tannic acid is considered to be a polyphenol inhibitor of amyloid aggregation and
found naturally in tea, red wine, and nuts. Based on previous studies performed to
studied its inhibition against prions (49), its mechanism is believed to be through direct
interactions with PrP. Considering inhibition was observed in all six strains but required
a high concentration for inhibition of HY when dissolved in DMSO, I predict that tannic
acid’s mechanism may be altered due to the specific biochemical characteristics of HY.
Congo red and Thioflavin T are both used as dyes in histological studies in order to
visualize amyloid deposits (96). These dyes are believed to interact with the b-pleated
sheet found in the secondary structure of amyloid aggregates (97). The usage of these
dyes as inhibitors would suggest that through inserts into the deposits, they prevent the
recruitment of PrPC by PrPSc. The lack of inhibition seen with ME7 for both of these
compounds would indicate that the unique conformation associated with this strain
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protects its b-pleated sheet and does not allow for the molecules to bind. As for the other
five strains, these dyes may not only be interrupting the conversion process by (1)
blocking the interaction between PrPC and PrPSc but also (2) obstructing the ability for
PrPSc to misfold properly thus further disrupting the assembly of the aggregate.
Quinacrine is considered to be an anti-malaria treatment (98). Concerning
quinacrine as a treatment option against prions, studies have been conducted in cell
models, animal models and in human clinical trials. In cell model studies tested against
scrapie, it was reported that quinacrine reduces the growth of abnormal prion protein
deposits (49); however, when tested against chronic wasting disease, it aided in the
accumulation of PrPSc (99). When administered in mice models against a mouse adapted
BSE strain, a decrease in PrPSc was described (100) and had no effect in humans with
sporadic CJD patients (101). Since numerous of studies indicted the decrease in PrPSc
levels, I believe that the mechanism of quinacrine would be at the protein-protein level
which makes my technique of 96wp-PMCA a viable platform to test this theory.
Considering no inhibition was observed against any of the strains, possible explanations
for this could be (1) quinacrine does not inhibit by binding to either forms of the prion
protein, (2) the usage of sonication breaks any interaction that may be form between
quinacrine and the prion protein, or (3) similar to chronic wasting disease, quinacrine
helps in the creation of PrPSc of the strains tested.
Similarities can be seen between prion diseases and other neurogenerative
diseases, such as Alzheimer’s and Parkinson’s disease. These diseases are associated
with the misfolding of proteins and histological dyes such as thioflavin to bind to misfolded
protein aggregates despite the protein composition of these aggregates (95). Based on
this knowledge, I postulated that anti-amyloid molecules may be effective in inhibiting
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prions as well. The anti-amyloid molecules (Figures 13 & 14) tested in this project have
been shown to inhibit the aggregation of protein linked to Alzheimer’s and Parkinson’s
disease. Azure A, azure B, azure C, and thionin acetate all belong to a class of drugs
called phenothiazines (76) and have all been shown to inhibit Aβ aggregation and tau
filament formation. Rhodanine inhibits the aggregation of tau (102) and quinacrine
mustard is considered to be a structural relative of quinacrine which in turn may have a
different inhibitory effect. When comparing the anti-amyloid molecules’ effectiveness
against the mouse prion strains (Figure 13) in comparison to the anti-prion molecules, I
was able to see that two of the molecules inhibited prion replication at a concentration
as low as 1 µM. This contrasts with the lowest concentration found for the anti-prion
molecules, from which the most effectives worked at a minimum concentration of 10 µM.
The difference in the chemical structure of azure C in comparison to azure A and azure
B can be the reasoning behind the lower concentration of inhibition seen when tested
against HY.
Inhibition was seen with all four phenothiazines. When azure A and azure B were
used in mouse models against AD, it was shown to stimulate protein degradation (103).
Assuming these molecules are not selective towards amyloid-b and various inhibition
concentrations seen between these two molecules along with azure C for the six strains,
the inhibitions seen can be attributed to the success of each molecule to promote PrP
degradation. Due to the utilization of PMCA to evaluate these molecules, I am unable to
determine which form of the prion protein is targeted. Azure A, azure B, and thionin
acetate are used as a dye and their mechanism of binding is through intercalation (104).
Since thioflavin T follows a similar mode of action, I believe that these three molecules
could be behaving very similar to thioflavin T. Comparing the structures of these
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compounds to thioflavin T, they all have three cyclic structures. Further studies would be
required; however, these structures could aid in their intercalation into the misfolded
protein.
It is important to note that quinacrine is typically accepted as a good anti-prion
drug compared to its structural relatives (75, 100); however, for the hamster strains, I am
able to see a better performance for quinacrine mustard instead of the parental structure.
The difference in inhibition could be as a result of the presence of the two chloride
functional groups attached to the quinacrine mustard dihydrochloride. Because inhibition
with quinacrine mustard was only seen with hamster prion strains binding to cofactors
necessary for prion misfolding which are present in the hamster brain extract but not in
the mouse counterpart may assist in the species-specific inhibitory effect of this
molecule. Further in silico studies may assist in clarifying the relationship between small
molecule composition and their interaction with prions in a strain-specific manner.
It is important to mention that due to the great sensitivity and strength of the PMCA
technology (93), it is not surprising that some molecules worked at lower concentrations
compared to the ones described using other systems. In that sense, the novel anti-prion
activity of some molecules from the “anti-amyloid” group look promising for future studies.
Unfortunately, due to the constraint of the technique utilized, the molecules were only
tested for their ability to inhibit protein-protein interactions. This could also explain the
lack of inhibition seen for some of the previously described anti-prion molecules working
at nanomolar concentrations in cell-based systems (49). Despite six of all the molecules
showing no inhibition at the concentration tested, strain-specific inhibition can be seen
for five of the molecules in hamster prions and four of the molecules in mouse prion
strains. When comparing the molecules between both mice and hamsters, further strain
specific inhibition can be seen. Based on these results, my original hypothesis is
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supported and confirm the need for strain-specific treatment options. I believe that the
current PMCA format can easily be applied towards testing a library of compounds
showing to inhibit other amyloids, as well as larger libraries. The optimization of PMCA
for high throughput screening will provide for another route to find treatment options for
prions along with being utilized in the diagnostic process of prion disease. Another benefit
and application of the HT-PMCA technique is the ability to apply it towards the study of
proteins involved in other neurodegenerative diseases, such as, Alzheimer’s and
Parkinson’s.
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